Figure 1.
Increasing dosages of the oxybutynin transdermal delivery system show dose-dependent increases in plasma concentrations of oxybutynin and N-desethyloxybutynin (DEO). Between dosages of 2.6 mg/d and 5.2 mg/d, the ratio of oxybutynin to DEO stays about the same. Data from Davila GW et al. J Urol. 2001;166:140–145.11